In addition, IHC for MelanA is also an effective identification method, which is positive in 90 % and 60 % of TFEB-associated renal cell carcinomas and TFEB-amplified renal cell carcinomas, respectively.[10] Another differential point is epithelioid angiomyolipoma, both of which show significant IHC overlap, consistently label melanocyte markers and cathepsin K, usually label CD117 and vimentin. Here, TFEB is linked to hereditary clear cell renal cell carcinoma.